A vaccine to combat the newer strains of Covid-19 has been approved and will be available to New Zealanders in time for winter 2024.

Medsafe has approved Pfizer’s application for an updated Covid-19 vaccine for the XBB.1.5 strain to be used in New Zealand says Medsafe Group Manager Chris James.

“Following a robust and efficient approval process the vaccine will be used to help reduce next year’s winter load on our hospitals," says Chris.

“The series of changes we see in the Covid-19 virus means we need to continually reassess and update our response to it.”

Pharmac – Te Pātaka Whaioranga has been working to secure supply of the updated vaccines in time for next winter season.

Pharmac’s Director, Pharmaceuticals Geraldine MacGibbon says it’s important to ensure we have the best available protection as we head towards the winter season.

“Securing Covid-19 vaccine stock for 2024 is a high priority for Pharmac," says Geraldine.

“We’re working with the suppliers, Medsafe, and Health New Zealand – Te Whatu Ora, to ensure New Zealanders have access to the Covid-19 XBB.1.5 vaccine in time for people to protect themselves and their whānau ahead of winter.

“We understand people are interested in who will have access to the Covid-19 XBB.1.5 vaccine when it’s available. There are no changes to eligibility at present.

"If Pharmac were to consider changes that would affect people’s access, we’d consult publicly to ensure we’re incorporating feedback from the healthcare sector and the community into our decision.”